We are live on ! Find out more
LCG

Lisanti Capital Growth Portfolio holdings

AUM $397M
1-Year Est. Return 178.66%
This Fund
S&P 500
This Quarter Est. Return
+50.21%
1 Year Est. Return
+178.66%
3 Year Est. Return
+1,089.72%
5 Year Est. Return
+3,176.57%
10 Year Est. Return
+120,936.2%
AUM
$723M
AUM Growth
+$183M
Cap. Flow
+$2.46M
Cap. Flow %
0.34%
Top 10 Hldgs %
18.74%
Holding
158
New
48
Increased
40
Reduced
30
Closed
31

Top Buys

Rank Stock Value
1
COHR icon
Coherent
COHR
+$9.57M
2
TEX icon
Terex
TEX
+$7.87M
3
PD icon
PagerDuty
PD
+$7.71M
4
LUNG icon
Pulmonx
LUNG
+$7.67M
5
ARWR icon
Arrowhead Research
ARWR
+$6.65M

Sector Composition

Rank Sector Weight
1 Healthcare 28.34%
2 Technology 27.5%
3 Industrials 19.61%
4 Consumer Discretionary 17.32%
5 Financials 3.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TEX icon
26
Terex
TEX
$7.54B
$9.31M 1.29%
+266,725
New +$7.87M
CDLX icon
27
Cardlytics
CDLX
$22M
$9.29M 1.29%
6,509
+3,610
+125% +$3.85M
SAIL
28
DELISTED
SailPoint Technologies Holdings, Inc. Common Stock
SAIL
$9.13M 1.26%
171,399
+7,950
+5% +$373K
WMS icon
29
Advanced Drainage Systems
WMS
$11.3B
$9.07M 1.26%
108,573
-21,060
-16% -$1.49M
CRNC icon
30
Cerence
CRNC
$410M
$8.94M 1.24%
88,940
-36,305
-29% -$2.71M
SWAV
31
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$8.85M 1.22%
85,325
+2,125
+3% +$184K
YETI icon
32
Yeti Holdings
YETI
$3.98B
$8.77M 1.21%
128,054
+3,580
+3% +$212K
TPTX
33
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$8.42M 1.17%
69,125
+6,210
+10% +$680K
QTWO icon
34
Q2 Holdings
QTWO
$3.93B
$8.35M 1.16%
65,971
-20,250
-23% -$2.18M
ARWR icon
35
Arrowhead Research
ARWR
$12.1B
$7.98M 1.1%
+103,955
New +$6.65M
LAD icon
36
Lithia Motors
LAD
$8.25B
$7.85M 1.09%
26,818
+630
+2% +$172K
PATK icon
37
Patrick Industries
PATK
$2.9B
$7.73M 1.07%
169,640
+44,588
+36% +$1.89M
APLS
38
DELISTED
Apellis Pharmaceuticals
APLS
$7.72M 1.07%
+134,945
New +$5.71M
RBC icon
39
RBC Bearings
RBC
$18.1B
$7.7M 1.06%
+42,980
New +$6.56M
OCUL icon
40
Ocular Therapeutix
OCUL
$1.92B
$7.58M 1.05%
+366,040
New +$5.44M
RGEN icon
41
Repligen
RGEN
$8.96B
$7.33M 1.01%
38,261
+280
+0.7% +$50.9K
CDNA icon
42
CareDx
CDNA
$2.35B
$7.32M 1.01%
+100,965
New +$5.85M
AEIS icon
43
Advanced Energy
AEIS
$13.1B
$7.16M 0.99%
+73,790
New +$6.28M
SDGR icon
44
Schrodinger
SDGR
$1.35B
$6.93M 0.96%
+87,505
New +$5.5M
EYE icon
45
National Vision
EYE
$1.82B
$6.82M 0.94%
150,670
-55,115
-27% -$2.4M
PLUG icon
46
Plug Power
PLUG
$2.86B
$6.6M 0.91%
194,563
+11,840
+6% +$268K
NSTG
47
DELISTED
NanoString Technologies, Inc.
NSTG
$6.51M 0.9%
+97,280
New +$4.88M
GDOT icon
48
Green Dot
GDOT
$762M
$6.45M 0.89%
115,563
+3,735
+3% +$212K
RCKT icon
49
Rocket Pharmaceuticals
RCKT
$389M
$6.28M 0.87%
114,568
+31,560
+38% +$1.15M
NEO icon
50
NeoGenomics
NEO
$2.01B
$6.23M 0.86%
115,748
+3,240
+3% +$146K

Similar funds

Lisanti Capital Growth's Q4 2020 Portfolio in Review

As of Q4 2020, Lisanti Capital Growth held 158 positions worth $723M, up 34% from $540M the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Lisanti Capital Growth's Q4 2020 filing shows 48 new, 40 increased, 30 reduced and 31 closed positions. Its largest new stake was Coherent: 161,475 shares worth $12.3M. The largest sale was Builders FirstSource, an estimated $12.3M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 25% a quarter earlier, followed by Technology and Industrials.

  • Lisanti Capital Growth's largest Q4 2020 buy was Coherent: 161,475 shares worth $12.3M.
  • Lisanti Capital Growth added most to Boot Barn in Q4 2020, an estimated $6.35M increase.
  • Lisanti Capital Growth's biggest Q4 2020 reduction was Builders FirstSource, cutting an estimated $12.3M.
  • Lisanti Capital Growth fully exited Tandem Diabetes Care in Q4 2020, selling an estimated $11.4M.
  • Lisanti Capital Growth's ten largest holdings make up 19% of its $723M portfolio in Q4 2020.
  • Lisanti Capital Growth opened 48 new positions and closed 31 in Q4 2020.
  • Lisanti Capital Growth's portfolio value rose 34% quarter-over-quarter to $723M.

Based on Lisanti Capital Growth's 13F filing for Q4 2020, filed 10 Feb 2021.